The prevalence of diabetes is escalating, and is leading to increased rates of heart failure, myocardial infarction and cardiovascular death. Due to several inter-related biological processes, hypertension is often associated with diabetes, and accelerates these morbid conditions. These points are outlined below.
Introduction
The ageing population, together with increasing urbanization and obesity, is the driving force behind the current epidemic of Type 2 diabetes mellitus (T2DM), which is projected to almost double from 171 million in 2000 to 334 million by 2025. 1 The association of T2DM with obesity, hypertension and dyslipidaemia, implies exponentially increasing rates of atherosclerotic vascular disease, cardiomyopathy and renal disease.
Numerous complex metabolic, neurovascular, genetic and hormonal factors increase the risk of developing hypertension or T2DM when the other already exists. The association of hypertension with T2DM is consistent across most, if not all populations. [2] [3] [4] Prospective studies have shown incidence rates of hypertension in DM to be three times that of subjects without DM. 5, 6 The reverse also applies, with the incidence of diabetes two to three times higher in patients with hypertension than those without. 7, 8 This review aims to assess the current burden of diabetes and hypertension, together with their associated complications. It will also discuss why diabetes and hypertension co-exist, and have synergistic adverse effects on cardiac function.
Search method
The English language literature was searched using Ovid, Medline and related databases from 1996 to May 2008, using various combinations of the terms 'heart disease', 'diabetes', 'hypertension' and 'high blood pressure'. References relevant to the relationship and adverse cardiovascular (CV) effects of diabetes and hypertension in the articles found were also reviewed.
Cardiovascular risk of diabetes and hypertension
The individual effects of DM and hypertension on outcome are well defined. The risk of CV death in DM alone has been reported to be analogous to that of the non-diabetic post-infarct patient, 9 although this seems to be overstated in younger patients. 10 Likewise, a meta-analysis performed by the Prospective Studies Collaboration found that CV mortality doubled for each 20/10 mm Hg increase in blood pressure, 11 with the association holding true for blood pressures as low as 115/75 mm Hg. The Framingham data demonstrated a high populationattributable risk of hypertension for the development of heart failure, accounting for 39% of cases in men and 59% of cases in women. 12 The co-existence of hypertension and diabetes is associated with disproportionate risk of mortality (Figure 1 ), 9,13-15 coronary heart disease ( Figure 2 ), 2, [15] [16] [17] [18] total CV events (Table 1) 4,15,18-20 and renal disease (Table 2) . 21, 22 Two observations emphasize the degree to which hypertension contributes to diabetes-related morbidity and mortality. On the one hand, minimal complications were identified in 92 patients with long-standing (440 years) DM in the absence of hypertension. 23 In contrast, newly diagnosed DM in the presence of hypertension is more likely to be associated with microalbuminuria, a history of CV disease or ECG evidence of left ventricular hypertrophy (LVH) than in non-hypertensive subjects, 24 with more diabetes-related morbidity and mortality (OR 1.56) from macrovascular disease over 3 years of follow-up. 15 There is no blood pressure threshold for the development of diabetic complications, including death, myocardial infarction, heart failure, stroke and microvascular disease; decreasing systolic pressure to o120 mm Hg conferred further protection in this study. 18 Outcome after CV events is also worse in subjects with DM. In patients with myocardial infarction or angina, the 5 year mortality was 11% in the absence of DM, 22% in those with DM and 26% in those with DM and unrecognized hypertension. 3 Moreover, the results of the Strong Heart Study (no hypertension or CV disease at baseline) suggest that incident CV disease (observed over 12 years) was associated with both pre-hypertension (120- Figure 2 Effects of hypertension (HT) and diabetes (DM), alone and together, in comparison with the absence of both, on coronary heart disease presentations. The figure summarizes ranges and mean of coronary heart disease (CHD) presentations per 1000 patient years. Numerators and denominators correspond to events and study participants, with event rates per 1000 patient years are listed in parentheses.
140/80-90 mm Hg) and pre-diabetes (impaired fasting glucose or glucose tolerance). 19 Subjects with DM and pre-hypertension were almost four times as likely to have an event as normotensive, nondiabetic subjects. Similarly, a prospective study of 2500 non-diabetics found that 10 year CV mortality was more than double in those with impaired (compared with normal) glucose tolerance, even after adjusting for incident diabetes and other CV risk factors. 8 Microvascular outcomes, such as proliferative retinopathy and renal failure, are also more likely in patients with both DM and hypertension. 18 Even in adolescents with Type 1 DM (T1DM), the development of retinopathy parallels the level of systolic and diastolic blood pressure. 25 
Mechanisms of the hypertensiondiabetes interaction
Contribution of hypertension to risk in the diabetic heart Hypertension has effects on the heart and vessels that predispose to LVH and fibrosis. Both LV (left ventricular) diastolic and systolic impairment may ensue, leading to heart failure.
LV hypertrophy. The hypertrophic LV is characterized by both myocyte hypertrophy and interstitial fibrosis. Hypertension was the major cause of LVH in the Framingham cohort, together with increasing age, obesity, myocardial infarction and valvular disease. 26 The prevalence of LVH varies from 19% in untreated hypertensive patients to 35% in those with hypertension that is difficult to control; 27,28 this finding is more common in men than women. 26, 28 The presence of LVH is associated with adverse outcome, with all-cause mortality being 56% higher for men with LVH, and more than double for those with associated ST depression, compared with patients with a normal ECG. 28 Increasing LV mass is also associated with incident hypertension, with a 26.5 g m À1 increase in mass leading to a 20% increased chance of developing hypertension. 29 Although some of the normotensive subjects may have been masked hypertensives, another explanation is that hypertension and LVH have a common aetiology (genetic factors, obesity, dyslipidaemia, insulin resistance and neuro-hormonal factors).
Fibrosis. Although fibrosis usually occurs in parallel with myocyte hypertrophy in LVH, it seems probable that these pathologies have separate mediators. LVH is identified in animal models of hypertension, irrespective of cause, but only aetiologies associated with elevation of aldosterone or angiotensin II (Ang II) were associated with interstitial fibrosis of left and right ventricles. 30 Imbalances of a number of locally produced promoters and inhibitors may potentially account for the Numerators and denominators correspond to events and study participants; event rates per 1000 patient years are listed in parentheses. Numerators and denominators correspond to events and study participants; event rates per 1000 patient years are listed in parentheses.
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Myocardial ischaemia. Coronary artery disease (CAD) is common to both DM and hypertension, and contributes to cardiac dysfunction and the risk of CV (including sudden) death. Patients with either DM or hypertension have an increased burden of silent myocardial ischaemia. 32, 33 Hypertension also predisposes to ischaemia based on increased workload, impaired LV filling and capillary rarefaction because of disproportionate growth of myocytes and interstitial tissue compared to capillary networks. Diffusion distances for oxygen and fuel sources are increased, and coronary flow reserve is decreased. Hypertensive subjects have a reduced myocardial blood flow reserve in response to adenosine, and a lower resting relative blood volume than patients with physiologic hypertrophy, indicating lower capillary density. 34 Endothelial dysfunction may account for a component of coronary flow reduction that is unexplained by the degree of hypertrophy. Hypertensive patients with chest pain and normal coronary angiography show reduced endothelial dependent vasodilatation in response to acetylcholine, 35 and a greater propensity to coronary spasm in response to ergonovine. 36 The correlation of reduced coronary flow reserve with diastolic LV pressures rather than LV mass is consistent with the theory that elevated diastolic intramyocardial pressures contribute an extra-vascular component to coronary resistance. 37 Nonetheless, endomyocardial biopsy studies have shown that abnormal microvascular findings are associated with myocyte hypertrophy and perivascular and replacement fibrosis. 38 Ventriculo-arterial mismatch. Hypertension accelerates the steady loss of compliance of the aorta associated with normal ageing. 39 This process is associated with alterations in LV structure and function. For example, in the LIFE study, arterial stiffness was correlated with concentric LV geometry and diastolic impairment in hypertensive patients with LVH but no prior events. 40 Similar findings have been reported in hypertensive patients with exertional dyspnoea and no evidence of ischaemic heart disease. 41 Increased afterload, together with common causative factors (Ang II, advanced glycation end product accumulation), could explain the association.
Contribution of diabetes to risk in the hypertensive heart Hypertension is an important companion to the association of diabetes with increased CV morbidity and mortality, in the development of atherosclerosis, heart failure and chronic kidney disease. However, there are also direct effects of DM on LV function.
Coronary artery disease. CAD manifests an aggressive phenotype in DM, in which it most commonly presents as three-vessel disease, in contrast to subjects without DM, among whom single-vessel disease was the most common finding. 42 The CAD outcomes in DM may be modified by a prothrombotic tendency. Platelet levels of plasminogen activator inhibitor 1 correlate with fasting insulin levels and are elevated in DM. 43 The increase in residual ADPinduced platelet aggregation despite dual antiplatelet therapy correlates with HbA1c levels. 44 Diabetic cardiomyopathy. The diabetic cardiomyopathy is independent of hypertension and CAD. The original description was of autopsy findings of four cases of idiopathic heart failure, in the setting of diabetic glomerulosclerosis. 45 The patients had LVH because of myocyte hypertrophy and interstitial fibrosis. Intramural arterioles had subendothelial thickening and medial hypertrophy in one case. More recently, this condition has been detected as subclinical systolic or diastolic dysfunction in, otherwise, healthy DM. LVH and abnormal myocardial perfusion are usually absent at this stage of disease.
Interstitial changes. Chronic hyperglycaemia leads to accumulation of non-enzymatically crosslinked advanced glycation end products, in which glucose is covalently bound to collagen and other proteins, leading to increased myocardial stiffness and vascular intimal thickening. An echocardiographic study compared LV function and integrated backscatter (a marker of myocardial reflectivity that generally represents the presence of collagen in the heart) in asymptomatic subjects with diabetes or LVH or both. 46 All the three groups had increased backscatter compared to controls, and all had reduced diastolic (Em) and systolic (systolic strain and strain rate) function. Systolic function was poorest in the group with both diabetes and hypertrophy. In the Strong Heart Study, diabetes was found to be associated with LVH and systolic dysfunction, independently of hypertension. 47 Diabetic subjects also had higher pulse pressure/ stroke volume ratio, indicating increased aortic stiffness. LV dysfunction is very common in, otherwise, well diabetic subjects. The prevalence of diastolic dysfunction in a group of diabetic subjects with no hypertension or ischaemic heart disease (excluded by angiography or stress echo) was shown to be 75%. 48 Vascular changes. Microvascular abnormalities have also been consistently found in diabetic heart disease. In a study of transthoracic Doppler-acquired, dipyridamole stress coronary flow reserve, 49 patients with DM and hypertension demonstrated reduced flow reserve, which was largely attributable to LVH, although diabetes and hypertension status were also significant influences. Similarly, young Diabetic hypertensive heart B Franjic and TH Marwick men with type 1 diabetes, a normal stress echo and no microalbuminuria or proliferative retinopathy, demonstrated reduced coronary flow reserve in response to dipyridamole, using PET scanning. 50 Interestingly, abnormal strain and strain rate do not correlate with impaired flow reserve, 51 suggesting that perfusion abnormalities may not account for the LV dysfunction.
Studies of the myocardial stress response in diabetes have provided conflicting results. One study showed that patients with DM, a normal dobutamine echo and no hypertrophy showed reduced resting systolic and early diastolic tissue velocities (Sm and Em) compared with controls with a similar prevalence of hypertension, but incremented both parameters normally with dobutamine. 52 These results contrast with another study using strain rate and strain, which found the systolic long axis response to dobutamine in DM to be impaired. 53 The higher prevalence of hypertrophy in the DM group may have influenced the result. Although the diabetic heart manifests histological and functional abnormalities of the microvasculature, the evidence that ischaemia contributes to the cardiac dysfunction seen in early diabetic cardiomyopathy is not complete.
Metabolic disturbances. Metabolic derangements within cardiomyocytes have been described in both animal and human DM, and likely contribute to reduced LV performance. Insulin resistance is associated with alterations in fuel usage, reduction in glucose and lactate metabolism and increased fatty acid uptake and usage. This predisposes to lipotoxicity-build up of intracellular fatty acids, which can cause myocyte dysfunction through increased oxidative stress and mitochondrial uncoupling, and apoptosis, triggered by ceramide accumulation. Animal models have shown that restoring normal metabolic pathways by transgenic increase in glucose transport activity (GLUT1 and GLUT4) or PPAR-g agonism can increase glucose usage, decrease fatty acid usage and improve cardiac function. 54, 55 PET studies in T1DM, obese and insulin resistant subjects have shown that these metabolic derangements are also present in humans, 56, 57 and correlate with reduced cardiac efficiency. These abnormalities of fuel usage and cardiac efficiency may impair cardiac reserve in the setting of ischaemia and other insults.
The abnormalities of calcium handling are also seen in diabetic myocardium. Animal diabetic models have shown impairment of release and reuptake of intracellular calcium by sarcoplasmic reticulum, and transgenic over-expression of SER-CA 2 (calcium reuptake pump) prevented LV dysfunction in a diabetic model. 58 Human studies have had limited ability to prove a significant effect of abnormal calcium handling in the development of diabetic cardiomyopathy.
Dysautonomia. Autonomic neuropathy is another complication of diabetes that can contribute to cardiac dysfunction. Reduced sympathetic activity can be demonstrated with SPECT (I 123 -MIBG), and is associated with systolic and diastolic dysfunction, 59 perhaps through loss of sympathetic effects on myocyte calcium currents and perfusion defects. The abnormalities with exercise include reduction in peak heart rate, blood pressure and cardiac output. 60 Parasympathetic/sympathetic imbalance may also predispose to repolarization abnormalities and malignant arrhythmias.
Interaction of diabetes and hypertension
The preceding descriptions of hypertensive and diabetic influences on CV structure and function illustrate many similarities. In isolation, either condition may be associated with LVH, with myocyte hypertrophy and interstitial fibrosis. Intramyocardial arteriosclerosis and coronary endothelial dysfunction predispose to ischaemia in the absence of epicardial coronary stenoses. The vascular remodelling leads to reduced arterial compliance, increased pulse pressure, and resting and exercise-induced increase in LV afterload. Increased sympathetic activation is present. The abnormalities of systolic and diastolic function are seen in the absence of significant valvular or coronary disease. Both conditions independently increase the risk of atherosclerosis and of heart failure. Many of the factors driving these changes are similar in both hypertension and diabetes, and the co-existence of both conditions has been shown to amplify these pathological processes (Table 3) . [61] [62] [63] [64] As both hypertension and diabetes lead to the development of serious vascular disease, it is easy to understand how their effects are additive, but how are they synergistic? There are a few clues regarding their multiplicative effects from the analysis of small arteries from gluteal fat biopsies, which provide information about both structure (media: lumen ratio, eutrophic vs hypertrophic remodelling) and function (vasodilator response). Hypertension leads to eutrophic remodelling (re-arrangement of media around smaller lumen). Remodelling of subcutaneous arteries has been associated with impaired coronary flow reserve in hypertensive humans (suggesting a generalized arteriosclerotic process), 65 and with increased risk of CV events in subjects with either diabetes or hypertension. 66 Diabetes leads to hypertrophic remodelling (increase in absolute volume of media-smooth muscle hypertrophy and/or extra-cellular matrix growth). 67 This pattern has also been reported in subjects with renovascular hypertension and primary aldosteronism, but not in phaeochromocytoma, suggesting that Ang II and other growth factors may be important. 68, 69 Insulin's effect as a growth factor is also likely to stimulate vascular smooth muscle cell growth. 70 Insulin also stimulates the production of angiotenDiabetic hypertensive heart B Franjic and TH Marwick sinogen by rat vascular smooth muscle cells, which promotes further growth, both cellular hypertrophy and collagen and fibronectin production. 71, 72 Along with structural remodelling, hypertension and diabetes contribute to functional abnormalities of the circulation. Endothelial dysfunction is found in each condition, and is more pronounced in the presence of both. Insulin resistance is also frequently observed in hypertension, and the relationship between these abnormalities is difficult to dissect. The degree of insulin resistance has been shown to parallel the degree of endothelial dysfunction, as illustrated in a study of myocardial blood flow with PET imaging. 73 The presence of hypertension worsens both the endothelium-dependent and independent measures of coronary flow reserve in diabetic subjects.
Endothelial dysfunction may cause insulin resistance and hypertension through common intracellular signalling pathways, and may be present in both pre-hypertension and pre-DM. For example, endothelial dysfunction is reported in normotensive offspring of hypertensive subjects, 74 as is insulin resistance, despite normal carbohydrate metabolism. 75 Endothelial dysfunction associated with insulin resistance is also reported in first degree relatives of patients with T2DM, despite normal blood pressure and glucose levels. 76 Skeletal muscle blood flow may be an important mechanism that links insulin resistance, hypertension and DM. In obese, insulin-resistant subjects, insulin-induced increase in skeletal muscle blood flow is impaired, and reduced delivery of insulin and glucose to skeletal muscle may contribute to glucose intolerance. 77 In young lean subjects without diabetes, higher mean arterial pressure was associated with impairment of insulin-induced skeletal muscle blood flow and glucose uptake. 78 Sympathetic over-activity is also seen in both diabetes and essential hypertension and is more marked when both conditions are present. 79, 80 Insulin itself has sympatho-excitatory effects, and elevated sympathetic tone has been found in obese, insulin resistant persons. 77 Sympathetic tone contributes trophic effects on cardiomyocytes and vascular smooth muscle, and may be responsible for LVH and vascular remodelling that maintains hypertension. 81, 82 Renal sympathetic stimulation also activates renin-angiotensin-aldosterone axis, with further stimulation of cardiac and vascular growth. 83 Ang II also potentiates sympathetic activity through receptors on autonomic nerve endings. T2DM is associated with elevated renin-angiotensin-aldosterone activity, and insulin has been shown to stimulate angiotensinogen production in vascular smooth muscle cells in vitro. 71, 84 Increased oxidative stress and inflammation are other factors that contribute to endothelial dysfunction, insulin resistance and hypertension.
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Conclusions and clinical implications
The prognostic data and potential mechanisms underlying the adverse implications of hypertension associated with DM reviewed in the preceding sections provide a series of clues that should inform the management approach to these patients. These might be divided into general and specific steps.
The general steps relate to aggressive control of the various components of CV risk, and can lead to significant reductions in the rate of complications such as myocardial infarction, stroke, renal failure, heart failure and limb amputation. 88 Strict glycaemic control is important for microvascular outcomes, but did not demonstrate clear benefit for macrovascular risk reduction until recent publication of the late follow-up of UKPDS, 89 showing that early glycaemic control is beneficial for reducing coronary events. Guidelines recognize the continuum of risk associated with blood pressure and lipids, and advise treatment of 'high normal' blood pressure, and cholesterol at any level, in patients who have diabetes in addition to other factors, which increase their absolute CV risk. 90 Although lifestyle intervention and dietary advice have less impact on the metabolic profile and outcomes, they are an important adjunct to pharmacologic treatment, 91 and should be used. The specific strategies to address risk are currently limited by the availability of drugs for specific mechanisms, for example, crosslink breakers, and this will be a fertile field for future development. Diabetic hypertensive heart B Franjic and TH Marwick
